CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
IRLAB is developing a new treatment for Parkinson's disease to alleviate severe motor and psychotic symptoms. Their compound, IRL790, aims to reduce complications from existing therapies and improve patient outcomes through ongoing clinical trials.
This project’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting > 6 million people worldwide.
It’s the neurological disorder with the highest increase in death rates, prevalence, and disability-adjusted life-years (DALYs).
Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term use lead…
INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
